Rezolute, Inc.

# Signal Note: RA Capital Initiates RZLT Position RA Capital's $21.7M entry into Rezolute likely reflects conviction in RZ358, a GLP-1 receptor agonist for post-bariatric hypoglycemia (a narrow but clinically severe indication affecting ~30% of gastric bypass patients). The position timing suggests confidence ahead of anticipated Phase 2b data or regulatory milestones, as this indication has limited competitive options and potential for orphan drug designation, supporting a smaller but defensible market opportunity.